Lisa A. Kottschade, Vera J. Suman, Domingo G. Perez, Robert R. McWilliams, Judith S. Kaur, Thomas T. Amatruda III, Francois J. Geoffroy, Howard M. Gross, Peter A. Cohen, Anthony J. Jaslowski, Matthew L. Kosel and Svetomir N. Markovic A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma Cancer 119
Article first published online: 22 AUG 2012 | DOI: 10.1002/cncr.27760
Metastatic melanoma continues to remain a devastating disease with few treatment options. This study indicates that the addition of bevacizumab to the combination of nab-paclitaxel and carboplatin shows initially promising activity worthy of further investigation.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.